Decoding liver injury in cystic fibrosis: How to tell drug-induced liver injury from cystic fibrosis liver disease. [PDF]
Lee J +11 more
europepmc +1 more source
Induced Pluripotent Stem Cells (iPSC) and Their Use in Disease Modeling. [PDF]
Dorota A +9 more
europepmc +1 more source
Comparison of the Effect of CFTR Modulators <i>elexacaftor</i>/<i>tezacaftor</i>/<i>ivacaftor</i> and <i>lumacaftor</i>/<i>ivacaftor</i> via Serum Human Epididymis Protein 4 Concentration in <i>p.Phe508del-CFTR</i> Homozygous Cystic Fibrosis Patients. [PDF]
Pócsi M +13 more
europepmc +1 more source
Cystic Fibrosis Treatment Landscape: Progress, Challenges, and Future Directions. [PDF]
Yıldız CA +5 more
europepmc +1 more source
Treatment with CFTR Modulators for Cystic Fibrosis: What a Pediatric Gastroenterologist Needs to Know. [PDF]
Jimenez DG +3 more
europepmc +1 more source
Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data. [PDF]
Imrei M +11 more
europepmc +1 more source
Longitudinal Study on Clinical Predictors for Allergic Bronchopulmonary Aspergillosis in Children and Young People with Cystic Fibrosis Highlights the Impact of Infection with Aspergillus and Pseudomonas and Ivacaftor Treatment. [PDF]
Chesshyre ELD +4 more
europepmc +1 more source
Intestinal current measurement detects age-dependent differences in CFTR function in rectal epithelium. [PDF]
Graeber SY +8 more
europepmc +1 more source
Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO. [PDF]
Chan CL +16 more
europepmc +1 more source

